Sai Life SciencesNSE:SAILIFE +1.35%18 EBITDA Margin % is 31.95% as of Mar. 2026, which is 48% above its 10-year median of 21.60. GuruFocus rates NSE:SAILIFE with a GF Score™ of 18/100. The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Sai Life Sciences ranks better than 89.71% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sai Life Sciences's EBITDA for the
three
months ended in Mar. 2026 was ₹1,924 Mil. Sai Life Sciences's Revenue for the
three
months ended in Mar. 2026 was ₹6,021 Mil. Therefore, Sai Life Sciences's EBITDA margin for the quarter that ended in Mar. 2026 was 31.95%.
Sai Life Sciences (NSE:SAILIFE) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sai Life Sciences EBITDA Margin % Related Terms
Sai Life Sciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sai Life Sciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SAILIFE vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Sai Life Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Life Sciences EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sai Life Sciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sai Life Sciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Life Sciences (NSE:SAILIFE) has a EBITDA Margin % of 31.95% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sai Life Sciences and its competitors. This is 48% above median its historical median of 21.60. Over the past decade, Sai Life Sciences' EBITDA Margin % has ranged from 16.12 to 30.66. According to the industry distribution chart, Sai Life Sciences ranks #21 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 10.3%.
Is Sai Life Sciences' EBITDA Margin % too high?
Sai Life Sciences' current EBITDA Margin % of 31.95% is 48% above median its 10-year median of 21.60. Over the past 10 years, this metric has ranged from a low of 16.12 to a high of 30.66. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. Sai Life Sciences' value of 31.95% is 514.4% above this industry median. Based on the distribution chart, Sai Life Sciences ranks #21 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Sai Life Sciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sai Life Sciences' EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Sai Life Sciences ranks #21 out of 204 companies for EBITDA Margin %. This places Sai Life Sciences in the top 10% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.20. Sai Life Sciences' value of 31.95% is 514.4% above this benchmark. Historically, Sai Life Sciences' own EBITDA Margin % has ranged from 16.12 to 30.66 over the past decade. While the company's 10-year median is 21.60 vs. the industry median of 5.20, Sai Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sai Life Sciences's current EBITDA Margin % of 31.95% is 514.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sai Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Life Sciences's current EBITDA Margin % is 31.95%, which is 48% above median its own 10-year median of 21.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Life Sciences stock overvalued right now?
Sai Life Sciences (NSE:SAILIFE) has a current EBITDA Margin % of 31.95%. The current EBITDA Margin % is 31.95%, which is 48% above median its 10-year median of 21.60 and 514.4% above the Medical Diagnostics & Research industry median of 5.20. Sai Life Sciences' overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sai Life Sciences (NSE:SAILIFE), the current EBITDA Margin % is 31.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Life Sciences Ltd is an innovator-focused, contract research, development, and manufacturing organization. It provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to pharmaceutical innovator companies and biotechnology firms. It possesses both; discovery/contract research (CRO) and chemistry, manufacturing, and control (CMC)/contract development and manufacturing organization (CDMO) capabilities. The company has only one reportable segment: contract research, development, and manufacturing. Geographically it operates in India as well as Outside India.
18GF Score
Get the complete analysis for NSE:SAILIFE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAILIFE has been successfully added to your 
